FDA has approved Reyvow, a new treatment for patients with migraine
The FDA ( U.S. Food and Drug Administration ) has approved Reyvow ( Lasmiditan ) tablets for the acute treatment of migraine with or without aura ( a sensory phenomenon or visual disturbance ) in adults.
Reyvow is not indicated for the preventive treatment of migraine.
Migraine headache pain is often described as an intense throbbing or pulsing pain in one area of the head.
Additional symptoms include nausea and/or vomiting and sensitivity to light and sound.
Approximately one-third of individuals who suffer from migraine also experience aura shortly before the migraine.
An aura can appear as flashing lights, zig-zag lines, or a temporary loss of vision.
Migraines can often be triggered by various factors including stress, hormonal changes, bright or flashing lights, lack of food or sleep, and diet.
Migraine is three times more common in women than in men and affects more than 10% of people worldwide.
The effectiveness of Reyvow for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials.
A total of 3,177 adult patients with a history of migraine with and without aura treated a migraine attack with Reyvow in these studies.
In both studies, the percentages of patients whose pain resolved and whose most bothersome migraine symptom ( nausea, light sensitivity, or sound sensitivity ) resolved two hours after treatment were significantly greater among patients receiving Reyvow at all doses compared to those receiving placebo.
Although patients were allowed to take a rescue medication two hours after taking Reyvow, opioids, barbiturates, triptans and ergots were not allowed within 24 hours of the study drug’s administration.
Twenty-two percent of patients were taking a preventive medication for migraine.
There is a risk of driving impairment while taking Reyvow. Patients are advised not to drive or operate machinery for at least eight hours after taking Reyvow, even if they feel well enough to do so. Patients who cannot follow this advice are advised not to take Reyvow.
The drug causes central nervous system ( CNS ) depression, including dizziness and sedation. It should be used with caution if taken in combination with alcohol or other CNS depressants.
The most common side effects that patients in the clinical trials reported were dizziness, fatigue, a burning or prickling sensation in the skin ( paresthesia ), and sedation. ( Xagena )
Source: FDA, 2019
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...
Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
The coronavirus disease 2019 ( COVID-19 ) virus, emerged in December 2019, has spread rapidly, with cases now confirmed in...
The FDA ( U.S. Food and Drug Administration ) has approved Isturisa ( Osilodrostat ) oral tablets for adults with...
COVID-19 can have fatal consequences for people with underlying cardiovascular disease and cause cardiac injury even in patients without underlying...
Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
First-line treatment of EGFR-mutated non-small cell lung cancer: concurrent Osimertinib plus Gefitinib
First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell...
Newly diagnosed primary central nervous system lymphoma: Ibrutinib-based combination therapy has exhibited therapeutic benefit
Ibrutinib ( Imbruvica ) has shown single-agent activity in relapse / refractory ( R/R ) primary central nervous system lymphoma...
FDA has approved Emgality, the first treatment for episodic cluster headache that reduces the frequency of attacks
The FDA ( U.S. Food and Drug Administration ) has approved Emgality ( Galcanezumab-gnlm; Galcanezumab ) solution for injection for...